ClinicalTrials.gg
TerminatedNCT03262116Updated Dec 9, 2022Results posted

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

A Phase 2/3 interventional study of Humalog and Novolog in Type 1 Diabetes Mellitus, sponsored by Massachusetts General Hospital. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Massachusetts General Hospital · Phase 2/3, Interventional, and Treatment

How we know

Why this study was terminated
Devices are not available

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
52nd of 69
20 · median 38
Started
2019
with 9 others
Phase 2/3
Only one
of the 69
Registered
38th of 69
by date

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 52nd largest by enrollment, is one of 10 that started in 2019, is the only one in phase 2/3, and was the 38th registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.

Read the detailed description

The investigators hypothesize that differences in the PK characteristics of insulin analogs will lead to differences in glycemic outcomes when delivered by the insulin-only configuration of the bionic pancreas. Specifically, the investigators predict that insulin analogs that have faster absorption (numerically lower Tmax and/or T½max) and insulin analogs that have faster clearance (numerically lower terminal half-life) will result in lower mean glucose and/or a lower percentage of time in the hypoglycemic range.

Up to 30 subjects will participate in three 7-day study arms using insulin lispro, insulin aspart, and BC222 lispro in the bionic pancreas in random order. The co-primary outcomes will be mean CGMG and fraction of time spent with CGMG \<54 mg/dl with comparisons made between arms for individual participants. Secondary analyses will include time in glycemic ranges (\<50, \<60, \<70, 70-120, 70-180, >180, >250 mg/dl), coefficient of variation, mean postprandial excursion (difference in CGMG from the time of meal announcement to the peak CGMG in the first 4 hours after the meal announcement) for both mixed meal challenges, number of symptomatic hypoglycemic events, grams of carbohydrate consumed to treat hypoglycemia, and TDD of insulin, between arms for individual subjects.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • bionic pancreas
  • insulin
  • continuous glucose monitor
  • type 1 diabetes
  • insulin pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and have had clinical type 1 diabetes for at least one year
  • Diabetes managed using an insulin pump for ≥ 6 months
  • Have used a CGM for at least one cumulative month over the last 12 months
  • Prescription medication regimen stable for > 1 month (except for medications that will not affect the safety of the study and are not expected to affect any outcome of the study, in the judgment of the principal investigator)
  • Willing to remain within a 250 mile radius of MGH. No air travel will be allowed, and subjects will still be expected to follow the visit schedule as described.
  • Willing to wear one Dexcom CGM sensor, and one leur-lock compatible infusion set that must be replaced every other day
  • Have a mobile phone they will have access to at all times during the study for making contact with study staff

Exclusion criteria

Exclusion Criteria:

  • Unable to provide (e.g. impaired cognition or judgment)
  • Unable to safely comply with study procedures and reporting requirements (e.g. impairment of vision or dexterity that prevents safe operation of the bionic pancreas, impaired memory, unable to speak and read English)
  • Current participation in another diabetes-related clinical trial that, in the judgment of the principal investigator, will compromise the results of this study or the safety of the subject
  • Pregnancy (positive urine HCG), breast feeding, plan to become pregnant in the immediate future, or sexually active without use of Subjects must use acceptable contraception for the two weeks prior to the study, throughout the study and for the two weeks following the study.

Acceptable contraception methods include: Oral contraceptive pill (OCP), Intrauterine Device (IUD, hormonal or copper), Male condoms, Female condoms, Diaphragm or cervical cap with spermicide, Contraceptive patch (such as OrthoEvra), Contraceptive implant (such as Implanon, Nexplanon), Vaginal ring (such as NuvaRing), Progestin shot (such as Depo-Provera), Male partner with a vasectomy proven to be effective by semen analysis

  • Current alcohol abuse (intake averaging > 3 drinks daily in last 30 days) or other substance abuse (use within the last 6 months of controlled substances other than marijuana without a prescription)
  • Unwilling or unable or to avoid use of drugs that may dull the sensorium, reduce sensitivity to symptoms of hypoglycemia, or hinder decision making during the period of participation in the study (use of beta blockers will be allowed as long as the dose is stable and the subject does not meet the criteria for hypoglycemia unawareness while taking that stable dose, but use of benzodiazepines or narcotics or other central nervous system depressants, even if by prescription, may be excluded according to the judgment of the principal investigator)
  • Renal failure requiring dialysis
  • Estimated \<15 mL/min/1.732
  • Personal history of cystic fibrosis, severe pancreatitis, pancreatic tumor, pancreatectomy or any other pancreatic disease leading to diabetes mellitus.
  • Any known history of coronary artery disease including, but not limited to, history of myocardial infarction, stress test showing ischemia, history of angina, or history of intervention such as coronary artery bypass grafting, percutaneous coronary intervention, or enzymatic lysis of a presumed coronary occlusion)
  • Abnormal consistent with coronary artery disease or increased risk of malignant arrhythmia including, but not limited to, evidence of active ischemia, prior myocardial infarction, proximal LAD critical stenosis (Wellen's sign), prolonged (> 440 ms). Non-specific ST segment and T wave changes are not grounds for exclusion in the absence of symptoms or history of heart disease. A reassuring evaluation by a cardiologist after an abnormal EKG finding may allow participation.
  • Congestive heart failure (established history of CHF, lower extremity edema, paroxysmal nocturnal dyspnea, or orthopnea)
  • History of or stroke15. Recent history of diabetic ketoacidosis (DKA) or severe hypoglycemia in the last 6 months. Severe hypoglycemia is defined as an event that required assistance of another person due to altered consciousness, and required another person to actively administer carbohydrate, glucagon, or other resuscitative actions. This means that the participant was impaired cognitively to the point that he/she was unable to treat himself/herself, was unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced seizure or coma.
  • History of more than 1 episode of DKA requiring hospitalization in the last 2 years
  • History of more than 1 episode of severe hypoglycemia in the last year.
  • Untreated or inadequately treated mental illness (indicators would include symptoms such as psychosis, hallucinations, mania, and any psychiatric hospitalization in the last year), or treatment with anti-psychotic medications that are known to affect glucose regulation.
  • Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference
  • Unable to completely avoid acetaminophen for duration of study
  • Established history of allergy or severe reaction to adhesive or tape that must be used in the study
  • History of eating disorder within the last 2 years, such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight
  • History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
  • Use of oral (e.g. thiazolidinediones, biguanides, sulfonylureas, glitinides, DPP-4 inhibitors, SGLT-2 inhibitors) or non-insulin injectable (GLP-1 agonists, amylin) anti-diabetic medications
  • Any diagnosed allergy to insulin lispro or insulin aspart
  • Lives in or frequents areas with poor Verizon wireless network coverage (which would prevent study staff from contacting subjects)
  • Any factors that, in the opinion of the principal investigator would interfere with the safe completion of the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Bionic Pancreas - Humalog

    Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.

    Drug: Humalog · Device: Bionic Pancreas

  • Experimental
    Bionic Pancreas - Novolog

    Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.

    Drug: Novolog · Device: Bionic Pancreas

  • Experimental
    Bionic Pancreas - BC222 insulin lispro

    Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.

    Drug: BC222 insulin lispro · Device: Bionic Pancreas

Interventions

  • DrugInsulin LisproStudies of Insulin LisproInsulin Lispro pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.

    Also known as: insulin

  • DrugInsulin AspartStudies of Insulin AspartInsulin Aspart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.

    Also known as: insulin

  • DrugInsulinStudies of InsulinInsulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.

    Also known as: insulin

  • DeviceBionic Pancreas

    The insulin-only bionic pancreas will be used in all three arms of the study

06

What researchers measure

Primary outcomes

  1. Average Continuous Glucose Monitor (CGM) Glucose

    The average glucose achieved by the bionic pancreas as measured by the continuous glucose monitor during each arm

    Time frame: 7 days

  2. Percentage of Time Spent With CGM Glucose < 54 mg/dl

    The amount of time the subject spent in the hypoglycemic range \< 54 mg/dl as measured by the continuous glucose monitor during each arm

    Time frame: 7 days

Secondary outcomes

  1. Percentage of Time Spent Within Each of the Following Ranges:

    The amount of time subject's spent in each of the listed glucose ranges as measured by the continuous glucose monitor during each bionic pancreas arm

    Time frame: 7 days

  2. Within Day Coefficient of Variation

    A measure of dispersion of glucose values around the mean

    Time frame: 7 days

  3. Mean Post Prandial Excursion

    Difference in CGMG from the beginning of the meal challenge to the peak CGMG in the 4 hours after the meal, for both mixed meal challenges.

    Time frame: 7 days

  4. Number of Symptomatic Hypoglycemic Events Per Day

    The number of times subjects report experiencing symptoms of hypoglycemia during each bionic pancreas arm

    Time frame: 7 days

  5. Grams of Carbohydrates Consumed to Treat Hypoglycemia Per Day

    The total amount of grams of carbohydrates subjects report having to take in for treatment of hypoglycemia

    Time frame: 7 days

  6. Total Daily Dose of Insulin

    The average total amount of insulin delivered daily by the bionic pancreas during each bionic pancreas arm.

    Time frame: 7 days

07

Results

Posted Dec 9, 2022
Limitations and caveats
The study was terminated, so only a limited number of participants completed all three interventions.

Participant flow

Participant flow — Overall Study
MilestoneInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 Lispro
Started232222
Completed211110
Not completed021112
Withdrew: Physician decision021112

Outcome measures

PrimaryAverage Continuous Glucose Monitor (CGM) Glucose

The average glucose achieved by the bionic pancreas as measured by the continuous glucose monitor during each arm

Time frame:
7 days
Reported as:
Mean · mg/dl
Average Continuous Glucose Monitor (CGM) Glucose
mg/dlInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Average Continuous Glucose Monitor (CGM) Glucose157.0 ± 9.2151.4 ± 13.1151.2 ± 13.8
PrimaryPercentage of Time Spent With CGM Glucose < 54 mg/dl

The amount of time the subject spent in the hypoglycemic range \< 54 mg/dl as measured by the continuous glucose monitor during each arm

Time frame:
7 days
Reported as:
Mean · percentage of CGM glucose values
Percentage of Time Spent With CGM Glucose < 54 mg/dl
percentage of CGM glucose valuesInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Percentage of Time Spent With CGM Glucose < 54 mg/dl0.30 ± 0.530.55 ± 0.261.01 ± 0.70
SecondaryPercentage of Time Spent Within Each of the Following Ranges:

The amount of time subject's spent in each of the listed glucose ranges as measured by the continuous glucose monitor during each bionic pancreas arm

Time frame:
7 days
Reported as:
Mean · percentage of CGM glucose values
Percentage of Time Spent Within Each of the Following Ranges:
percentage of CGM glucose valuesInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
% time CGM glcuose < 50 mg/dl0.20 ± 0.420.24 ± 0.210.63 ± 0.50
% time CGM glcuose < 60 mg/dl0.80 ± 0.881.31 ± 0.551.85 ± 1.05
% time CGM glcuose < 70 mg/dl2.65 ± 1.713.59 ± 1.714.31 ± 1.66
% time CGM glcuose 70-120 mg/dl27.49 ± 5.0427.20 ± 5.5330.44 ± 5.57
% time CGM glcuose 70-180 mg/dl67.77 ± 8.5772.16 ± 10.3470.06 ± 10.25
% time CGM glcuose >180 mg/dl29.58 ± 7.7924.26 ± 9.2925.63 ± 9.02
% time CGM glcuose > 250 mg/dl7.67 ± 3.555.21 ± 5.247.11 ± 6.41
SecondaryWithin Day Coefficient of Variation

A measure of dispersion of glucose values around the mean

Time frame:
7 days
Reported as:
Mean · percentage of CGM glucose values
Within Day Coefficient of Variation
percentage of CGM glucose valuesInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Within Day Coefficient of Variation37.4 ± 4.135.5 ± 7.838.6 ± 7.8
SecondaryMean Post Prandial Excursion

Difference in CGMG from the beginning of the meal challenge to the peak CGMG in the 4 hours after the meal, for both mixed meal challenges.

Time frame:
7 days
Reported as:
Mean · mg/dl
Mean Post Prandial Excursion
mg/dlInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Mean Post Prandial Excursion95.06 ± 37.49103.13 ± 47.37104.07 ± 36.60
SecondaryNumber of Symptomatic Hypoglycemic Events Per Day

The number of times subjects report experiencing symptoms of hypoglycemia during each bionic pancreas arm

Time frame:
7 days
Reported as:
Mean · number of events
Number of Symptomatic Hypoglycemic Events Per Day
number of eventsInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Number of Symptomatic Hypoglycemic Events Per Day0.73 ± 0.430.60 ± 0.431.02 ± 0.67
SecondaryGrams of Carbohydrates Consumed to Treat Hypoglycemia Per Day

The total amount of grams of carbohydrates subjects report having to take in for treatment of hypoglycemia

Time frame:
7 days
Reported as:
Mean · grams of carbohydrates
Grams of Carbohydrates Consumed to Treat Hypoglycemia Per Day
grams of carbohydratesInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Grams of Carbohydrates Consumed to Treat Hypoglycemia Per Day12.42 ± 11.599.27 ± 6.9414.00 ± 11.95
SecondaryTotal Daily Dose of Insulin

The average total amount of insulin delivered daily by the bionic pancreas during each bionic pancreas arm.

Time frame:
7 days
Reported as:
Mean · units per kilogram per day
Total Daily Dose of Insulin
units per kilogram per dayInsulin-only Bionic Pancreas With BC222 LisproInsulin-only Bionic Pancreas With Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart
Total Daily Dose of Insulin0.71 ± 0.160.60 ± 0.210.61 ± 0.25

Adverse events

Collected over 1 week of study participation using each insulin, for a total of up to three weeks of study intervention. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Insulin-only Bionic Pancreas With BC222 Lispro0/8 (0%)0/8 (0%)0/8 (0%)
Insulin-only Bionic Pancreas With Insulin Lispro0/8 (0%)0/8 (0%)0/8 (0%)
Insulin-only Bionic Pancreas With Insulin-aspart0/9 (0%)0/9 (0%)0/9 (0%)

Baseline characteristics

20 participants consented to participate. 13 participants were randomized to complete three weeks using the insulin-only bionic pancreas. Only 6 completed all three arms. The numbers listed in the participant flow, and throughout the record only represent unique participants. Dyads, including designated contacts, are not used. No data was collected from designated contacts that is relevant to this protocol.

Age, Continuous
Age, Continuous(years)Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 LisproTotal
Mean30.0 ± 14.140.7 ± 17.670.5 ± 14.833.0 ± 9.947.0 ± 14.150.0 ± 15.647.8 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 LisproTotal
Female0212117
Male2110116
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 LisproTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000101
White23221212
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 LisproTotal
United States23222213
Hemoglobin A1c
Hemoglobin A1c(percent of glycated hemoglobin)Insulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With BC222 Lispro, Then Insulin Aspart, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Lispro, Then BC222 Lispro, Then Insulin AspartInsulin-only Bionic Pancreas With Insulin Lispro, Then Insulin Aspart, Then BC222 LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then BC222 Lispro, Then Insulin LisproInsulin-only Bionic Pancreas With Insulin Aspart, Then Insulin Lispro, Then BC222 LisproTotal
Mean6.7 ± 0.86.9 ± 0.96.9 ± 0.26.2 ± 0.57.2 ± 0.86.4 ± 0.56.7 ± 0.6
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jul 2019, 4 months.

Results were first posted in Dec 2022, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2017
First posted
Aug 25, 2017
StartActual
Mar 19, 2019
Primary completionActual
Jul 23, 2019
CompletionActual
Jul 23, 2019
Results first posted
Dec 9, 2022
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03262116
Collaborators
Boston University
Responsible party
Steven J. Russell, MD, PhD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 25, 2017
Start date
Mar 19, 2019
Primary completion
Jul 23, 2019
Completion
Jul 23, 2019
Results posted
Dec 9, 2022
Last update
Dec 9, 2022

Study contacts

Steven J Russell, MD, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin Aspart · Insulin

Start the discussion